|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS10526 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200 |
| CAS編號 | |
| 抗體名 | Anti-PSMA7/Proteasome 20S alpha 7 |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human Proteasome 20S alpha 7 |
產(chǎn)品訂購信息：
英文名稱 Anti-PSMA7/Proteasome 20S alpha 7
中文名稱 蛋白酶體PSMα7抗體規(guī)格
別 名 C6 antibody HSPC; Proteasome (prosome macropain) subunit alpha type 7; Proteasome alpha 7 subunit; Proteasome subunit alpha 4; Proteasome subunit alpha type 7; Proteasome subunit alpha type-7; Proteasome subunit RC6 1; Proteasome subunit RC6-1; Proteasome subunit XAPC7; PSA7_HUMAN; PSMA7; RC6 1; XAPC7.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 發(fā)育生物學(xué) 干細(xì)胞 細(xì)胞周期蛋白 細(xì)胞分化 細(xì)胞類型標(biāo)志物
蛋白分子量 predicted molecular weight: 28kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human Proteasome 20S alpha 7
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
蛋白酶體PSMα7抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Plays an important role in the regulation of cell proliferation or cell cycle control, transcriptional regulation, immune and stress response, cell differentiation, and apoptosis. Interacts with some important proteins involved in transcription factor regulation, cell cycle transition, viral replication and even tumor initiation and progression. Inhibits the transactivation function of HIF-1A under both normoxic and hypoxia-mimicking conditions. The interaction with EMAP2 increases the proteasome-mediated HIF-1A degradation under the hypoxic conditions. Plays a role in hepatitis C virus internal ribosome entry site-mediated translation. Mediates nuclear translocation of the androgen receptor (AR) and thereby enhances androgen-mediated transactivation. Promotes MAVS degradation and thereby negatively regulates MAVS-mediated innate immune response.
Function : The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. Plays an important role in the regulation of cell proliferation or cell cycle control, transcriptional regulation, immune and stress response, cell differentiation, and apoptosis. Interacts with some important proteins involved in transcription factor regulation, cell cycle transition, viral replication and even tumor initiation and progression. Inhibits the transactivation function of HIF-1A under both normoxic and hypoxia-mimicking conditions. The interaction with EMAP2 increases the proteasome-mediated HIF-1A degradation under the hypoxic conditions. Plays a role in hepatitis C virus internal ribosome entry site-mediated translation. Mediates nuclear translocation of the androgen receptor (AR) and thereby enhances androgen-mediated transactivation. Promotes MAVS degradation and thereby negatively regulates MAVS-mediated innate immune response.
Subunit : The 26S proteasome consists of a 20S proteasome core and two 19S regulatory subunits. The 20S proteasome core is composed of 28 subunits that are arranged in four stacked rings, resulting in a barrel-shaped structure. The two end rings are each formed by seven alpha subunits, and the two central rings are each formed by seven beta subunits. The catalytic chamber with the active sites is on the inside of the barrel. PSMA7 interacts directly with the PSMG1-PSMG2 heterodimer which promotes 20S proteasome assembly. Interacts with -1 TAT protein. Interacts with hepatitis B virus X protein (HBX). Interacts with HIF1A. Interacts with RAB7A. Interacts with PARK2. Interacts with ABL1 and ABL2. Interacts with EMAP2. Interacts with MAVS.
Subcellular Location : Cytoplasm. Nucleus.
Similarity : Belongs to the peptidase T1A family.
Database links : UniProtKB/Swiss-Prot: O14818.1
Anti-CMKLR1/CHEMR23/FITC 熒光素標(biāo)記趨化樣因子受體1抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-phospho-JAK2(Tyr221) /FITC 熒光素標(biāo)記磷酸化蛋白酪氨酸激酶JAK-2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh CCDC67 卷曲螺旋結(jié)構(gòu)域蛋白67抗體 規(guī)格 0.2ml
HLA-DR(human leukoyte Antigen DR) HLA-DR抗原 0.5mg
HOMER2 英文名稱： HOMER2抗體 0.2ml
Rhesus antibody Rh SNF5 轉(zhuǎn)錄調(diào)控激活蛋白SNF5抗體 規(guī)格 0.2ml
Anti-phospho-JAK2(Tyr221) /FITC 熒光素標(biāo)記磷酸化蛋白酪氨酸激酶JAK-2抗體IgGMulti-class antibodies規(guī)格： 0.2ml
FSP(Human Fibroblast surface protein) ELISA Kit 人纖維母細(xì)胞表面抗原Multi-class antibodies規(guī)格： 48T
Anti-PKA 蛋白激酶A抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh HIPK2 Fas相互作用蛋白激酶2抗體 規(guī)格 0.2ml
PABA(Mouse para-aminobenzoic acid) ELISA Kit 小鼠對基苯 96T
PSCD1 英文名稱： 胞粘蛋白1抗體抗體 0.1ml
phospho-CREM (Ser271 +Ser 274) 英文名稱： 磷酸化環(huán)磷酸腺苷反應(yīng)元件調(diào)節(jié)蛋白抗體 0.1ml
Anti-PKA 蛋白激酶A抗體Multi-class antibodies規(guī)格： 0.2ml
UU-Ab(Human Ureaplasma urealyticum antibody) ELISA Kit 人解脲脲原體抗體Multi-class antibodies規(guī)格： 48T
Anti-MAdCAM-1 粘膜定居因子抗體Multi-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Keratocan 細(xì)胞角膜蛋白多糖抗體 規(guī)格 0.2ml
OT/BGP ELISA Kit 大鼠骨鈣素/骨谷酸蛋白 96T
phospho-PTK9 (Ty*1) 英文名稱： 磷酸化蛋白酪酸激酶9抗體 0.1ml
Phospho-CHK2 (ser19) 英文名稱： 磷酸化細(xì)胞周期檢測點(diǎn)激酶2抗體 0.1ml
Anti-MAdCAM-1 粘膜定居因子抗體Multi-class antibodies規(guī)格： 0.2ml
CL-0460U14-GFP(小鼠子細(xì)胞)5×106cells/瓶×2
AACS Others Human 人 AACS / Acetoacetyl-CoA 桿狀病毒-昆蟲細(xì)胞裂解液 (陽性對照)
人顱骨造骨細(xì)胞RNAHCO miRNA5 μg
HL-60細(xì)胞，原髓細(xì)胞 人非小細(xì)胞細(xì)胞,NCI-H23細(xì)胞 MSC, 小鼠雪旺細(xì)胞
豚鼠胚胎細(xì)胞;104C1
CD226 Others Mouse 小鼠 DNAM-1 / CD226 人細(xì)胞裂解液 (陽性對照)
CL-0459U14(小鼠子細(xì)胞)5×106cells/瓶×2
CN3 Others Mouse 小鼠 Coactin 3 / CN3 人細(xì)胞裂解液 (陽性對照)
大鼠晶狀體上皮細(xì)胞完全培養(yǎng)基 100mL
EB (NBL-4)牛胚氣管細(xì)胞 EB (NBL-4) of bovine embryo acheal cells MEM培養(yǎng)基(GIBCO)+10%FBS
IL36G Protein Mouse 重組小鼠 IL36G / IL1F9 蛋白 (His 標(biāo)簽)
NCI-H446(人小細(xì)胞細(xì)胞) 5×106cells/瓶×2 HeLa(細(xì)胞)
蛋白酶體PSMα7抗體規(guī)格 小鼠骨髓間充質(zhì)肝細(xì)胞(MMSC-bm)(5×105)
人虹膜色素上皮細(xì)胞cDNAHIPEpiC cDNA
大鼠腦細(xì)胞;C6
雜交瘤(B類);Z1510C6D10F4G6 小鼠脈絡(luò)膜細(xì)胞完全培養(yǎng)基 100mL
HAVSMC, 人主動脈平滑肌細(xì)胞 Human
EFNA1 Others Mouse 小鼠 EFNA1 / Ephrin-A1 人細(xì)胞裂解液 (陽性對照)
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 蛋白酶體PSMα7抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時,或位于酶的催化位點(diǎn)時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）蛋白酶體PSMα7抗體規(guī)格 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
